tiprankstipranks
HCW Biologics Expands with New Financial Agreements
Company Announcements

HCW Biologics Expands with New Financial Agreements

Pick the best stocks and maximize your portfolio:

HCW Biologics ( (HCWB) ) has issued an announcement.

HCW Biologics Inc. has entered a $6.9 million securities purchase agreement with an institutional investor, involving a registered direct offering and a concurrent private placement of common stock and warrants. The offering, priced above market under NASDAQ rules, is expected to close shortly. The company is focused on developing innovative immunotherapies targeting inflammation and age-related diseases, and has secured a licensing deal for its preclinical candidate with WY Biotech, promising milestone payments and royalties.

See more insights into HCWB stock on TipRanks’ Stock Analysis page.

Related Articles
TheFlyHCW Biologics prices $6.9M registered direct offering at $1.03 per share
TheFlyHCW Biologics licenses proprietary preclinical molecule to WY Biotech
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App